Kiniksa Pharmaceuticals (KNSA) Expected to Announce Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is anticipated to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Kiniksa Pharmaceuticals to post earnings of ($0.06) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Kiniksa Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ:KNSA opened at $20.02 on Monday. The business has a 50 day moving average of $19.71 and a 200-day moving average of $22.67. The stock has a market cap of $1.45 billion, a PE ratio of -142.99 and a beta of 0.32. Kiniksa Pharmaceuticals has a 12-month low of $16.56 and a 12-month high of $28.15.

Insider Buying and Selling

In related news, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at $492,449.10. This trade represents a 28.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now owns 88,975 shares in the company, valued at $1,622,904. This represents a 13.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,092 shares of company stock worth $745,589 in the last three months. 54.57% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently commented on KNSA. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Evercore ISI raised their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.